C. Moltó

PATIENTS OPINION ON THE QUALITY OF CARE OFFERED IN INTERNAL MEDICINE DEPARTMENT WARDS IN AN SPANISH TEACHING HOSPITAL

E. Calabuig, J. Merino, P. Wikman, 2008 .

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period.

I. Gich, A. Barnadas, T. Hwang, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

A. Kesselheim, I. Gich, A. Barnadas, 2020, Cancer.

Association between control group therapy and magnitude of clinical benefit of cancer drugs

E. Amir, A. Tibau, J. C. Tapia, 2022, Scientific reports.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Arnoud J Templeton, C. Booth, A. Barnadas, 2018, Journal of the National Cancer Institute.

Three-year Disease-free Survival in Randomized Trials of Neoadjuvant Chemotherapy and HER2-targeted therapy in Breast Cancer: A meta-analysis.

Nicholas Meti, E. Amir, B. E. Wilson, 2022, Critical reviews in oncology/hematology.

Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.

H. Goldvaser, A. Ocaña, E. Amir, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review

D. Cescon, E. Amir, A. Mittal, 2023, Journal for ImmunoTherapy of Cancer.

Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis

P. Pérez-Segura, A. Ocaña, E. Amir, 2023, Frontiers in Immunology.

Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials

E. Amir, A. Mittal, C. Moltó, 2024, Heliyon.